ANL · Adlai Nortye Group Ltd.
Market Cap
$974.98M
Shares
64.40M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.01
Open$14.69
Day$14.55–16.02
52W close$0.88–16.60
Avg vol 30d154K
Short int4.3M · 6.7% float · 26.3d
Short vol54%
DataSep 2023–Sep 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-714.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+752.8%
Trailing year
Short interest
6.7%
Latest settlement · 26.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+67%
above
Price vs 50-day avg
+20%
above
RSI (14)
61
neutral
MACD trend
Positive
52-week position
90%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+13%
trailing
6-month return
+88%
trailing
YTD return
+957%
this year
Relative strength
+73%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
+62% holders QoQ · +22 funds added
Insider flow
Distributing
Net -$164.6K over 90 days · 100% sells
Short interest
Rising
6.67% of float · ▲ +2.9% MoM · 26.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
42 holders — near 3-yr high, broad support
Squeeze score
73
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
152%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+67%
Bullish
Price vs 50-day avg
+20%
Bullish
RSI (14)
61
Neutral
MACD trend
Positive
Bullish
52-week position
90%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $13 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
+62% holders QoQ · +22 funds added
Insider flow
Distributing
Net -$164.6K over 90 days · 100% sells
Short interest
Rising
6.67% of float · ▲ +2.9% MoM · 26.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
42 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $15 · 90%
Range high $17
vs 200-day avg +67%
vs 50-day avg +20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANL
this stock
Adlai Nortye Group Ltd.
|
$974.98M | +957.0% | — | — | 6.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.42B | +20.5% | +46.2% | 31.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.22B | +7.2% | +20.8% | 20.5 | 2.3% |
|
ARGX
Argenx SE
|
$62.63B | +22.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANL | +8.6% | +13.0% | +88.1% | +5.8% | +957.0% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | +8.5% | +13.4% | +73.0% | +5.4% | +944.1% |
Key facts
CIK
1944552
CUSIP
00704R109
13F (30d)
37 filings
37 filers
Visit website
Investor relations